Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes
- Lorenzo Piemonti1⇑,
- Matthew J. Everly2,
- Paola Maffi1,
- Marina Scavini1,
- Francesca Poli3,
- Rita Nano1,
- Massimo Cardillo3,
- Raffaella Melzi1,
- Alessia Mercalli1,
- Valeria Sordi1,
- Vito Lampasona4,
- Alejandro Espadas de Arias3,
- Mario Scalamogna3,
- Emanuele Bosi1,5,
- Ezio Bonifacio6,
- Antonio Secchi1,5 and
- Paul I. Terasaki2
- 1Diabetes Research Institute, San Raffaele Hospital Scientific Institute, Milan, Italy
- 2Terasaki Foundation Laboratory, Los Angeles, California
- 3Organ and Tissue Transplantation Immunology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- 4Center for Translational Genomics and Bioinformatics, Milan, Italy
- 5Vita-Salute San Raffaele University, Milan, Italy
- 6Center for Regenerative Therapies and Paul Langerhans Institute Dresden, Dresden University of Technology, Dresden, Germany
- Corresponding author: Lorenzo Piemonti, .
E.Bon., A.S., and P.I.T. contributed equally to this study.
Long-term clinical outcome of islet transplantation is hampered by the rejection and recurrence of autoimmunity. Accurate monitoring may allow for early detection and treatment of these potentially compromising immune events. Islet transplant outcome was analyzed in 59 consecutive pancreatic islet recipients in whom baseline and de novo posttransplant autoantibodies (GAD antibody, insulinoma-associated protein 2 antigen, zinc transporter type 8 antigen) and donor-specific alloantibodies (DSA) were quantified. Thirty-nine recipients (66%) showed DSA or autoantibody increases (de novo expression or titer increase) after islet transplantation. Recipients who had a posttransplant antibody increase showed similar initial performance but significantly lower graft survival than patients without an increase (islet autoantibodies P < 0.001, DSA P < 0.001). Posttransplant DSA or autoantibody increases were associated with HLA-DR mismatches (P = 0.008), induction with antithymocyte globulin (P = 0.0001), and pretransplant panel reactive alloantibody >15% in either class I or class II (P = 0.024) as independent risk factors and with rapamycin as protective (P = 0.006) against antibody increases. DSA or autoantibody increases after islet transplantation are important prognostic markers, and their identification could potentially lead to improved islet cell transplant outcomes.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1258/-/DC1.
See accompanying commentary, p. 1377.
- Received September 12, 2012.
- Accepted November 17, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.